Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > COMMENTARY
COMMENTARY
- 5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
- COMMENTARY：New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
- COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
- COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
- Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
- Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
- COMMENTARY 3 articles
June 19, 2006
- Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
- Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
- Incident in PI Trial in UK 5 articles
May 8, 2006
- COMMENTARY 3 articles
April 24, 2006
- New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
- Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
- JMA Needs to Establish New Partnership with LDP
April 17, 2006
- COMMENTARY 4 articles
April 3, 2006
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…